


# icling TM For dry mouth

## Orally dissolving films For dry mouth relief



#### 1 in every 5 people is likely to suffer from dry mouth

Xerostomia and Hyposalivation are two phenomena associated with dry mouth, or the hypofunction of the salivary glands.

They pose a major global problem, affecting approximately 20 percent of the general population, with significantly higher rates in specific populations (e.g., patients who undergo chemotherapy or radiation therapy for cancer).





#### Dry Mouth Seriously Affects Quality of Life

Dry mouth is a common side effect of many medications and medical procedures, such as chemotherapy and radiotherapy in cancer treatment. It may negatively affect quality of life, and may cause oral health problems such as halitosis, impaired chewing and swallowing, and difficulties in prosthesis retention. Lower salivary flow also increases the risk of dental caries, due to an absence of the physical cleaning and buffering action of saliva.

### PharMedica's Innovative Orally Dissolved Films (ODF) Technology

PharMedica's innovative orally dissolved films (ODF) technology is a substantial differentiator for generic drugs and other bioactive substances, enabling improved delivery of drugs and nutraceuticals.

#### Leading the Evolution of Oncology Supportive Care

PharMedica aims to redefine the supportive care of cancer patients through innovative drug delivery systems that provide controlled and sustained release of therapeutics. Our unique ODF technology has the potential of improving treatment efficacy, enhancing patient quality of life, and setting new standards in cancer supportive care.

#### iCling™ Advanced Product for Dry Mouth Relief

iCling<sup>™</sup> is PharMedica's first commercial ODF product, designed for relieving dry mouth symptoms. iCling<sup>™</sup> is based on PharMedica's proprietary adhesive polymeric delivery platform, combined with propriety saliva producing active substance.

The platform make-up is based on polymers and other excipients, which are all generally regarded as safe (GRAS), while the active substance is made of natural extracts.

#### As Easy as 1-2-3



**iCling**™ is completely dissolved once the active substances are released.

#### **Proven Effectiveness**

iCling™ was designed for controlled and sustained release of the active substance over several hours, markedly helping to alleviate the dry mouth symptoms. The product was tested on a focus group of patients and presented a long-lasting effect with high ease of use.

PharMedica's  $iCling^{m}$  for dry mouth relief has the potential to become the treatment of choice for dry mouth relief.

#### **Strong Intellectual Property**

PharMedica's ODF technology and  $iCling^{m}$  are protected by several patents. The product is pending FDA clearance and is in the process of certifications in several other jurisdictions.

#### **About PharMedica**

**PharMedica** is a biopharmaceutical company, that develops polymeric film-based delivery platforms, enabling controlled and sustained release of drugs, nutraceuticals and food additives.

**PharMedica** is leading the evolution of oncology supportive care through innovative drug delivery systems that provide controlled and sustained release of therapeutics.

The delivery platform is made of a unique and proprietary polymeric matrix, tailored to deliver multiple active substances, in a sustained and controlled manner, directly to the needed body parts, using an intraoral transmembrane delivery system. This innovative technology improves the bioavailability and effectiveness of therapeutic active substances.



PharMedica Ltd.
P. O. Box 15060,
Matam, Haifa 31905, Israel
+972-4-834-2155
info@pharmedica.co.il
www.pharmedica.co.il



